Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial" [Vaccine 40(19) (2022) 2705-2713]

Affiliations

• ¹ Department of Pathology and Laboratory Medicine, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA. Electronic address: Jessica.Crothers@uvmhealth.org.
• ² Microbiology and Molecular Genetics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.
• ³ Department of Pediatrics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.
• ⁴ Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
• ⁵ Department of Immunology and Microbiology, Tulane University, New Orleans, LA, USA.